Skip to main content

Advertisement

SpringerLink
Log in

Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA)

  • SYMPOSIUM – BIOLOGICAL THERAPIES: NEW INDICATIONS, CLINICAL AND PHARMACO-ECONOMIC ASSESSMENT
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) has become one of the most studied autoimmune chronic inflammatory diseases (ACIDs), either from the pathogenetic or from the therapeutic point of view. It is recognized that synovial fibroblasts, TH1 and TH17 cells likely play along with the B cells the most relevant role. The disease has a polygenic background that characterizes the seropositive and the seronegative subsets. Over the years, we realized that no more than 15–20% of long-standing RA (LSRA) treated with conventional drugs can reach full remission, whereas the most recent data in early RA (ERA) have demonstrated that 40–60% can be put into clinical and biological remission. This of course is of crucial importance to avoid any progression of the structural damage that leads to functional disability. If we consider that a disability index score (Health Assessment Questionnaire 0–3) of a severe arthritis can cost up to 21,000 EUs, while a mild disease will cost not more than 5,500 EUs per year, it appears very clear that a low disease activity (LDA) or a remission state (Rem) should be the aim in each single patient, in order to keep the workability and maintain the productivity. This is and should be the major aim in each RA patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Plenge RM (2009) Rheumatoid arthritis genetics: 2009 update. Curr Rheumatol Rep 11:351–356

    Article  PubMed  CAS  Google Scholar 

  2. Tolusso B, Frezza D, Mattioli C, Fedele AL, Bosello S, Faustini F, Peluso G, Giambra V, Pietrapertosa D, Morelli A, Gremese E, De Santis M, Ferraccioli GF (2009) Allele *2 of the HS1, 2 A enhancer of the Ig regulatory region associates with rheumatoid arthritis. Ann Rheum Dis 68:416–419

    Article  PubMed  CAS  Google Scholar 

  3. Orozco G, Eyre S, Hinks A, Bowes J, Morgan AW, Wilson AG, Wordsworth P, Steer S, Hocking L, UKRAG consortium, Worthington J, Barton A (2011) Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 70:463–468

    Article  PubMed  Google Scholar 

  4. Ria F, Penitente R, De Santis M, Nicolo’ C, Di Sante G, Orsini M, Arzani D, Fattorossi A, Battaglia A, Ferraccioli GF (2008) Collagen-specific T cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis. Arthritis Res Therapy 10:R135

    Article  Google Scholar 

  5. De Rosa MC, Giardina B, Bianchi C, Carelli Alinovi C, Pirolli D, Ferraccioli GF, De Santis M, Di Sante G, Ria F (2010) Modeling the ternary complex TCR-Vbeta/Collagen II (261–273)/HLA-DR4 associated with rheumatoid arthritis. PLoS ONE 5(7):e11550

    Article  PubMed  Google Scholar 

  6. Ria F et al. Unpublished

  7. Ferraccioli GF, Bracci-Laudiero L, Alivernini S, Gremese E, Tolusso B, De Benedetti F (2010) Interleukin 1 β and interleukin 6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. M O L M E D 1 6:552–557

    Google Scholar 

  8. Ferraccioli GF, Zizzo G (2011) The potential role of TH17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. Discovery Medicine 11:413–424

    PubMed  Google Scholar 

  9. Zizzo G, De Santis M, Bosello SL, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli GF (2011) Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. Clin Immunol 138:107–116

    Article  PubMed  CAS  Google Scholar 

  10. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, McFarlane JD (1994) Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha(cA2) in patients with rheumatoid arthritis. Lancet 344:1105–1110

    Article  PubMed  CAS  Google Scholar 

  11. Tanimoto K, Iwabuchi Y, Tanne Y, Kamiya T, Inubushi T, Mitsuyoshi T, Tanne K (2011) Interleukin 1 beta affects cyclooxygenase 2 expression and cartilage metabolism in mandibular condyle. Arch Oral Biol [Epub ahead of print]

  12. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD (2002) Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 61:704–713

    Article  PubMed  CAS  Google Scholar 

  13. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y (1995) Interleukin 6 induces the proliferation of synovial fibroblastic cells in the presence of soluble IL6 receptors. Br J Rheumatol 34:321–325

    Article  PubMed  CAS  Google Scholar 

  14. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S (1996) Interleukin-6 and soluble interleukin 6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88–95

    Article  PubMed  CAS  Google Scholar 

  15. Trebec-Reynolds DP, Voronov I, Heersche JN, Manolson MF (2010) IL1 alpha and IL1beta have different effects on formation and activity of large osteoclasts. J Cell Biochem 109:975–982

    PubMed  CAS  Google Scholar 

  16. Rutella S, De Cristofaro R, Ferraccioli GF (2009) Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Human Immunol 70:360–373

    Article  CAS  Google Scholar 

  17. Bosello S, Pers JO, Rochas C, Devauchelle V, De Santis M, Daridon C, Saraux A, Ferraccioli GF, Youinou P (2007) BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 20:1–8

    PubMed  CAS  Google Scholar 

  18. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli GF (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity and response to treatment in early rheumatoid arthritis. J Rheumatol 35:1256–1264

    PubMed  CAS  Google Scholar 

  19. Tolusso B, De Santis M, Bosello S, Gremese E, Gobessi S, Cuoghi I, Rumi C, Efremov DG, Ferraccioli GF (2009) Synovial B cells of rheumatoid arthritis express Zap-70 which increases the survival and correlates with the inflammatory and autoimmune phenotypes. Clin Immunol 131:98–108

    Article  PubMed  CAS  Google Scholar 

  20. Michelutti A, Gremese E, Morassi F, Petricca L, Arena V, Tolusso B, Alivernini S, Peluso G, Bosello SL, Ferraccioli GF (2011) B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and Zap-70 and characterize the aggregate pattern irrespectively of the autoantibody status. Mol Med [Epub ahead of print]

  21. Pietrapertosa D, Tolusso B, Gremese E, Papalia MC, Bosello S, Peluso G, Petricca L, Michelutti A, Faustini F, Fedele AL, Ferraccioli GF (2010) Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of the likelihood ratios. Clin Chem Lab Med 48:829–834

    Article  PubMed  CAS  Google Scholar 

  22. Neogi T et al (2010) The 2010 American College of Rheumatology/European League against Rheumatism classification criteria for rheumatoid arthritis. Phase 2 methodological report. Arthritis Rheum 62:2582–2591

    Article  PubMed  Google Scholar 

  23. Maini RN, StClair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 354:1932–1939

    Article  PubMed  CAS  Google Scholar 

  24. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, the CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829

    Google Scholar 

  25. Van der Linden MPM, Le Cessie S, Raza K, Van der Woude D, Knevel R, Huizinga TW, Van der Helm-Van Mil AH (2010) Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 62:3537–3546

    Article  PubMed  Google Scholar 

  26. Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, Van Riel PL, Vam de Laar MA (2011) Implementation of a treat to target strategy in very early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Rheum 63 [Epub ahead of print]

  27. Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli GF (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non- progression. Ann Rheum Dis 70:1292–1295

    Article  PubMed  Google Scholar 

  28. Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli GF (2011) Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis 70:172–175

    Article  PubMed  Google Scholar 

  29. Kobelt G (2006) Health economic issues in rheumatoid arthritis. Scand J Rheumatol 35:415–425

    Article  PubMed  CAS  Google Scholar 

  30. Emery P, Breedvel FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen MD, Koenig AS, Freundlich B (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375–382

    Article  PubMed  CAS  Google Scholar 

  31. Wolfe F, Michaud K, Choi HK, Williams R (2005) Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 32:1875–1883

    PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Institute of Rheumatology, School of Medicine, Catholic University of the Sacred Heart-CIC, Via Moscati 31, 00168, Rome, Italy

    Gianfranco Ferraccioli & Elisa Gremese

Authors
  1. Gianfranco Ferraccioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisa Gremese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gianfranco Ferraccioli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferraccioli, G., Gremese, E. Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). Intern Emerg Med 6 (Suppl 1), 11 (2011). https://doi.org/10.1007/s11739-011-0668-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11739-011-0668-6

Keywords

Search

Navigation